Logo-npj
Submitted: 21 Jun 2023
Accepted: 25 Aug 2023
ePublished: 20 Nov 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2024;13(1): e10641.
doi: 10.34172/npj.2023.10641
  Abstract View: 613
  PDF Download: 307

Mini Review

Nephrotoxicity of checkpoint inhibitors; a current challenge

Samaneh Zandifar 1 ORCID logo, Mahshid Imankhan 2 ORCID logo, Padideh Daneii 3 ORCID logo, Ali Azarpey 4* ORCID logo, Leila Alem 1* ORCID logo

1 Nickan Research Institute, Isfahan, Iran
2 Independent Researcher, 1514 Sheridan Rd NE apt 4014, Atlanta, Georgia, United States
3 Department of Cardiology, University of Florida Health, Jacksonville, Florida, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States
*Corresponding Authors: Ali Azarpey, Email: Ali.Azarpey2@emory.edu; Leila ALem, Email: leilaalem916@gmail.com

Abstract

Immune checkpoint inhibitors work by blocking the “checkpoint” mechanism that tumors use to hide from the immune system, therefore also weakening the immune system. Consequently, checkpoint inhibitors can cause autoimmune reactions, resulting in adverse effects. Prompt identification and management of adverse effects are critical for patients under checkpoint inhibitor therapy due to the potential severity and unpredictability of these immune-related adverse events.

Implication for health policy/practice/research/medical education:

Checkpoint inhibitors can cause various adverse effects that need close monitoring and management, as prompt identification and proper management are critical. Patients under checkpoint inhibitor therapy should undergo regular monitoring and close communication with their clinical team to identify the signs and symptoms of any adverse reactions that may arise and manage them effectively.

Please cite this paper as: Zandifar S, Imankhan M, Daneii P, Azarpey A, ALem L. Nephrotoxicity of checkpoint inhibitors; a current challenge. J Nephropharmacol. 2024;13(1):e10641. DOI: 10.34172/npj.2023.10641.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 614

Your browser does not support the canvas element.


PDF Download: 307

Your browser does not support the canvas element.